Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | ALB | P02768 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | TK1 | P04183 | 3/20 | 0.51 |
| ▸ | TK2 | O00142 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1471401 | 1.00 | LMNA (0.51) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL5930446 | 0.96 | LMNA (0.52) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL22819195 | 0.96 | LMNA (0.52) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL5930585 | 0.96 | LMNA (0.52) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL1468928 | 0.89 | TK1 (0.48) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL769371 | 0.89 | TK1 (0.48) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL12747393 | 0.89 | TK1 (0.48) | LMNAALBBLMALDH1A1POLB | |
| SCHEMBL1468851 | 0.86 | PYGM (0.62) | LMNABLMTK1TK2TSHR | |
| SCHEMBL1468849 | 0.86 | PYGM (0.62) | LMNABLMTK1TK2TSHR | |
| SCHEMBL13017964 | 0.86 | TK1 (0.49) | LMNAALBBLMALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | AUSPEX PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| WO-2005049582-A1 | METHOD OF PREPARATION OF NOVEL NUCLEOSIDE ANALOGS AND USES | AUSPEX PHARMACEUTICALS, INC. (US) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070192-A1 | Method of preparation of novel nucleoside analogs and uses | RNGTT, TYMP, SLC29A1 | LMNA 493/4885ALB 3889/4885BLM 1287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.